PALB2 and familial pancreatic carcinoma: The odds of germline deleterious variations involving BRCA2, PALB2, SPINK1, and CFTR were significantly greater in patients with pancreatic cancer in the Nanjing cohort than in those without pancreatic cancer from the ExAC cohort (control) (BRCA2: OR, 3.2 [95% CI, 1.4-7.7; P = .008]; PALB2: OR, 5.2 [95% CI, 1.6-17.0; P = .007]; SPINK1: OR, 3.2 [95% CI, 1.8-5.7; P < .001]; and CFTR: 5.7 [95% CI, 2.0-16.4; P = .001]) (Table 3); the odds of SPINK1 and CFTR stayed significant after Bonferroni correction.